Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pusintin
- Development stage
- Phase 3
- Lead developer
- TOT Biopharm
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pusintin is a biosimilar of bevacizumab, developed by TOT Biopharm. It is a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis—the formation of new blood vessels—which tumors need for growth and metastasis. Pusintin has been approved in China for the treatment of advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), glioblastoma multiforme, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma. The drug was developed using proprietary Perfusion-batch mixed culture technology to optimize production efficiency and cost[1][2][3][5][8].
- Brand names
- Pusintin
- Other names
- bevacizumab biosimilarTAB008TAB-008TAB 008
02
Targets
Beyond the preview
Go deeper on pusintin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pusintin.